Searched for
DILIP S SHANGHVI
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...- Ram Shriram's Sherpalo Ventures to lead $60 million funding round in Skyroot; valuation hits $1.1 billionGIC, of Singapore, BlackRock, Greenko Group founders take part in round along with Sun Pharma founder Dilip Shanghvi family office as the 9...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Sun's strong gravity helps India Inc's pullSun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Suzlon Energy shares fall over 3% after Dilip Shanghvi and Associates terminate 2020 pactShares of Suzlon Energy fell 3% to Rs 25 in Wednesday's trade on BSE after the Sun Pharma promoter Dilip Shanghvi and Associates decided to...
- Dilip Shanghvi & Associates terminate 2020 pact with Suzlon EnergyWith the termination of the agreement, the investor group's nominee director on Suzlon's board, Hiten Timbadia, has also resigned with effe...
- SPARC raises over Rs 1,110 cr; issues warrants to promoter Dilip Shanghvi, othersThe issue price includes the warrant subscription price (Rs. 44.50 per warrant) and the warrant exercise price (Rs. 133.50 per warrant).
- Aditya Medisales case: Sebi accepts settlement pleas of Sun Pharma, promotersSebi had initiated a probe against Sun Pharma, its managing director Dilip Shanghvi and its directors on the basis of two whistleblower com...
- Dilip Shanghvi, IDFC Bank, Telenor drop plans to set up payments bankThe decision to abandon plans to set up a payments bank was taken as the promoters felt that they lacked adequate physical presence in term...
- Competition Commission approves Dilip Shanghvi's proposed Rs 1,800-crore deal with SuzlonThe deal, announced in February this year, would see Shanghvi acquiring at least 23 per cent stake in Suzlon which has been grappling with ...
- Sun Pharma surges on reports Shanghvi likely to buy partial stake of Daiichi in company; ends day flatSun Pharma rose as much as 2.8 per cent to hit its intraday high of Rs 1066.40 on the BSE, after ET NOW reported the story.
- Dilip Shanghvi in talks for a stake buy in ABG ShipyardTroubled shipbuilder ABG Shipyard is looking for a white knight and it's now pinning hopes on India's richest man Dlilip Shanghvi for a bai...
- Suzlon Energy rallies nearly 20% on Sun Pharma promoter's open offerSuzlon Energy last week signed definitive agreements with Dilip Shanghvi Family and Associates (DSA) for equity investments of Rs 1,800 cro...
- Dilip Shanghvi diversifies to expand his business, makes big investments in power and bankingThis weekend, Shanghvi announced a Rs 1,400-crore investment to pick up 23% stake in ailing renewable energy company Suzlon through DSA.
- Dilip Shanghvi, associates make open offer for 26% stake in SuzlonThe open offer price for 157.64 crore shares is Rs 18 per scrip, a total of about Rs 2,837.52 crore.
- Sun Pharma's Dilip Shanghvi to acquire 23% in Suzlon Energy for Rs 1,800 croreSuzlon’s promoters will retain management control “by virtue of pooling arrangement for voting”, while the Shanghvi family will remain a fi...
- Sun Pharma chief Dilip S Shanghvi expects Ranbaxy deal to be closed by mid-FebruaryDilip S Shanghvi expects the Ranbaxy deal to be concluded by middle of next month while stating that the key challenge before the combined ...
- Why Dilip Shanghvi Shanghvi is all praise for the PMA master strategist, Dilip Shanghvi, promoter of Sun Pharma and ET’s business leader for 2014, has come a long way from the time he built h...
Load More
